<DOC>
	<DOCNO>NCT01866553</DOCNO>
	<brief_summary>The purpose trial ass effect switch CML patient , treat imatinib ≥ 2 year stable detectable molecular residual disease 0.01-1.0 % ( IS ) , combination Nilotinib PegIFN , term proportion patient achieve confirm MR4.0 .</brief_summary>
	<brief_title>Nilotinib Plus Pegylated Interferon-α2b CML</brief_title>
	<detailed_description>Study phase : Phase II . Patient population : Patients suboptimal molecular response stable detectable molecular residual disease ≥ 2 year treatment imatinib ( i.e . BCR ABL level 0.01 % 1 % IS ) . Study objective : To assess effect switch CML patient , treat imatinib ≥ 2 year stable detectable molecular residual disease 0.01-1.0 % ( IS ) , combination Nilotinib PegIFN , term proportion patient achieve confirm MR4.0 . Study design : Single arm , open label , multicenter study ass efficacy , safety tolerability nilotinib 300 mg BID , alone combination PegIFN 25 - 40 μg/week patient CMR . Patients treat nilotinib 300 mg BID begin study establish tolerability add PegIFN . Combination treatment continue Month 12 , follow monotherapy phase nilotinib 300 mg BID . Overall study duration individual patient 24 month .</detailed_description>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>1 . Patients ≥ 18 year 2 . At diagnosis CML chronic phase 3 . Documented complete cytogenetic response bone marrow ( standard cytogenetics ) peripheral blood BCR ABL &lt; 1 % IS 4 . Persistent disease demonstrate two PCR positive test ( i.e . BCR ABL level 0.01 % 1 % IS ) perform past 9 month 10 week apart . One perform within 1 month registration 5 . Treatment imatinib least 2 year 400 mg stable dose ( i.e . dose change previous 6 month ) 6 . No current plan anti leukemia therapies 7 . ECOG Performance status 0,1 , 2 8 . Adequate organ function define : 1 . Total bilirubin &lt; 1.5 x ULN . Does apply patient isolated hyperbilirubinemia ( e.g . Gilbert 's disease ) grade &lt; 3 . 2 . ASAT ALAT &lt; 2.5 x ULN . 3 . Serum amylase lipase ≤1.5 x ULN . 4 . Alkaline phosphatase ≤2.5 x ULN . 5 . Creatinine clearance &gt; 30 ml/min . 6 . Mg++ , K+ ≥LLN . 9 . Life expectancy &gt; 12 month absence intervention 10 . Patient give write informed consent 1 . Prior accelerate phase blast crisis . 2 . Patient receive another investigational agent within last 6 month . 3 . Previous treatment nilotinib dasatinib . 4 . Prior stem cell transplantation . 5 . Impaired cardiac function include one following : 1 . Inability monitor QT/QTc interval ECG . 2 . Long QT syndrome know family history long QT syndrome . 3 . Clinically significant rest brachycardia ( &lt; 50 bpm ) . 4 . QTc &gt; 450 msec baseline ECG ( use QTcF formula ) . If QTcF &gt; 450 msec electrolyte within normal range , electrolyte correct patient screen QTc . 5 . Myocardial infarction within 12 month prior start study . 6 . Other clinically significant uncontrolled heart disease ( e.g . unstable angina , congestive heart failure uncontrolled hypertension ) . 7 . History presence clinically significant ventricular atrial tachyarrhythmias . 6 . Known atypical BCR ABL transcript quantifiable standard RQ PCR 7 . History active malignancy past 5 year exception basal carcinoma skin carcinoma situ cervix uteri breast . 8 . Acute liver disease cirrhosis . 9 . Previous active acute chronic pancreatic disease . 10 . Another severe and/or life threaten medical disease . 11 . History significant congenital acquire bleed disorder unrelated cancer . 12 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption study drug . 13 . Patients actively receive therapy strong CYP3A4 inhibitor treatment either discontinue switched different medication prior start study drug . 14 . Patients currently receive treatment medication potential prolong QT interval treatment either discontinue switched different medication prior start study drug . 15 . Patients pregnant , breast feeding , childbearing potential without negative pregnancy test prior baseline ; male female childbearing potential unwilling use contraceptive precaution throughout trial ( post menopausal woman must amenorrheic least 12 month consider non childbearing potential ) . 16 . Interruption imatinib therapy cumulative period excess 21 day precede 3 month . 17 . Major toxicity imatinib past 3 month . 18 . History non compliance , inability grant inform consent . 19 . Past present history alcohol abuse , use illicit drug , severe psychiatric disorder , include depression . 20 . Known hypersensitivity interferon preparation . 21 . Autoimmune hepatitis history autoimmune disease . 22 . Pre exist thyroid disease unless controlled conventional treatment . 23 . Epilepsy and/or compromise central nervous system ( CNS ) function . 24 . HCV/HIV patient . 25 . Poorly control diabetes mellitus ( i.e . HbA1c &gt; 9.0 ) clinically relevant diabetic complication neuropathy , retinopathy , nephropathy , coronary peripheral vascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>CML</keyword>
	<keyword>suboptimal molecular response</keyword>
	<keyword>nilotinib</keyword>
	<keyword>pegylated interferon α2b</keyword>
</DOC>